Search

everythinglearnresearchcommunity

for

Search:↓

Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

No cure exists for alopecia areata, and treatments are personalized.

Tofacitinib may effectively regrow hair in alopecia totalis patients.

Alopecia areata is a complex condition causing hair loss, linked to genetics and immune system issues, and may be related to other autoimmune diseases; treatments vary in effectiveness.

Use telemedicine and strict hygiene for safe hair and scalp treatments during COVID-19.

Most patients with rheumatoid arthritis continued methotrexate treatment over two years, but those who stopped and restarted experienced more side effects and less improvement.

The document discusses hair and nail conditions, updates on treatments for alopecia, and controversies around finasteride use.

Laser therapy might help regrow hair in alopecia totalis better than steroids alone.

The document lists various dermatology topics, treatments, and diagnostic methods.

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

Pediatric dermatologists have varied preferences for treating alopecia areata in children, with no standard FDA-approved treatments and some using JAK inhibitors despite risks.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Dissolving microneedles show promise for treating hair loss but need more research for practical use.

Visual signs are crucial for accurately diagnosing and treating different types of hair loss in Black patients.

OXTR agonists may promote hair growth and be effective for treating hair loss.

Alopecia areata patients have a higher risk of blood clots.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

The PTH-CBD injection improved hair regrowth better than the daily ruxolitinib pill in mice.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

Blocking JAK3 signaling can reverse hair loss from alopecia areata.

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

Targeted cytokine treatments may help with alopecia areata, but more research is needed.

Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.